129 related articles for article (PubMed ID: 38156931)
61. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
62. Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell.
Lee S; Lee H; Jeong D; Ham J; Park S; Choi EH; Kim SJ
Free Radic Biol Med; 2017 Sep; 110():280-290. PubMed ID: 28666851
[TBL] [Abstract][Full Text] [Related]
63. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
[TBL] [Abstract][Full Text] [Related]
64. MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells.
Lee MH; Koh D; Na H; Ka NL; Kim S; Kim HJ; Hong S; Shin YK; Seong JK; Lee MO
Autophagy; 2018; 14(5):812-824. PubMed ID: 29130361
[TBL] [Abstract][Full Text] [Related]
65. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
[TBL] [Abstract][Full Text] [Related]
66. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors.
Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR
Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426
[TBL] [Abstract][Full Text] [Related]
67. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.
Ward A; Balwierz A; Zhang JD; Küblbeck M; Pawitan Y; Hielscher T; Wiemann S; Sahin Ö
Oncogene; 2013 Feb; 32(9):1173-82. PubMed ID: 22508479
[TBL] [Abstract][Full Text] [Related]
68. Relationship of micro-RNA, mRNA and eIF Expression in Tamoxifen-Adapted MCF-7 Breast Cancer Cells: Impact of miR-1972 on Gene Expression, Proliferation and Migration.
Behringer A; Stoimenovski D; Porsch M; Hoffmann K; Behre G; Grosse I; Kalinski T; Haybaeck J; Nass N
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883472
[TBL] [Abstract][Full Text] [Related]
69. Long Non-Coding RNA (lncRNA) 91H Confers Tamoxifen Resistance in ER+ Breast Cancer Cells through Inhibiting mTOR Signaling Pathway.
Lv ZY; Mo QP; Tang HC; Zheng SS
Ann Clin Lab Sci; 2022 Nov; 52(6):947-955. PubMed ID: 36564063
[TBL] [Abstract][Full Text] [Related]
70. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
Han X; Li Q; Liu C; Wang C; Li Y
J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
[TBL] [Abstract][Full Text] [Related]
71. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells.
Choi HK; Yang JW; Roh SH; Han CY; Kang KW
Endocr Relat Cancer; 2007 Jun; 14(2):293-303. PubMed ID: 17639045
[TBL] [Abstract][Full Text] [Related]
72. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
73. Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.
Fagan DH; Fettig LM; Avdulov S; Beckwith H; Peterson MS; Ho YY; Wang F; Polunovsky VA; Yee D
Horm Cancer; 2017 Aug; 8(4):219-229. PubMed ID: 28577281
[TBL] [Abstract][Full Text] [Related]
74. Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells.
Oh SJ; Kim O; Lee JS; Kim JA; Kim MR; Choi HS; Shim JH; Kang KW; Kim YC
Food Chem Toxicol; 2010 Nov; 48(11):3227-34. PubMed ID: 20804812
[TBL] [Abstract][Full Text] [Related]
75. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61.
Bauerschmitz G; Hüchel S; Gallwas J; Gründker C
Cancer Genomics Proteomics; 2023; 20(6):531-538. PubMed ID: 37889058
[TBL] [Abstract][Full Text] [Related]
77. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
[TBL] [Abstract][Full Text] [Related]
78. SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells.
Choi HK; Cho KB; Phuong NT; Han CY; Han HK; Hien TT; Choi HS; Kang KW
Mol Pharm; 2013 Jul; 10(7):2517-27. PubMed ID: 23763570
[TBL] [Abstract][Full Text] [Related]
79. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
80. CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation.
Wu X; Sun A; Yu W; Hong C; Liu Z
Mol Cell Endocrinol; 2020 Jul; 512():110866. PubMed ID: 32417506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
